Probably AF to beet the covering going to happen.
his incomplete leaves open to a bullish call on NWBO. Although he is not an analysts, analysts change sides rapidly. And he should turn before UCLA and MD Anderson doctors publish more reports. Remember the FDA is working very closely with NWBO and its trial designs. The FDA allowing multiple cancers in one phase is unheard of !
and CYBR catching most of new business!
CYBR going to $90+
CYBR going to $90+
Pe much cheaper than PANW and FEYE..$90+ for CYBR
(Reuters) - Neil Woodford, one of Britain's most famous fund managers due to his strong track record, has seen his new CF Woodford Equity Income fund given a 'Bronze' rating by fund analysts Morningstar.
It is the first time Morningstar has ranked the fund since it was launched to much fanfare earlier this year, after Woodford left Invesco Perpetual to start up his own company, WoodfordInvestment Management.
"The strategy of this fund is clear, and aims to generate a positive capital return in the long term and grow the income whilst offering capital preservation," Morningstar said in a statement on Tuesday.
"He has proven himself willing to stick to his strategy even during periods of poor performance. As a result, his long-term track record, which encompasses numerous market cycles, is strong," they added. (Reporting by Simon Jessop; editing by Carolyn Cohn
Can-Fite's leading proprietary compounds, CF101 and CF102, are centered on multi-billion dollar market opportunities. According to GlobalData, the psoriasis drug market is forecasted to grow from $3.6 billion in 2010 to $6.7 billion by 2018, while the rheumatoid arthritis drug market according to independent business information provider visiongain, is predicted to generate revenues of $38.5 billion by 2017. GIA projects that the global liver cancer drugs market will exceed $2 billion by 2015 and GlobalData projects that the glaucoma market to top $3 billion by 2018.
•Q4 2014 - Planning Phase III trials for rheumatoid arthritis following the release of positive Phase II study results.
•Q1 2015 – Announce data for Phase II/III trial for psoriasis with 300 patients for which Can-Fite has already received positive interim data from the first 100 patients .
•Q2/Q3 2015 – Announce data for the Phase II study for glaucoma with 88 patients.
•Q4 2014 - Patient enrollment has commenced for a Phase II trial in Israel, Europe and the U.S. for the treatment of patients with advanced liver cancer as a second line therapy
Major airline buzz.
In the midst of this truly positive news for CLDX and rGBM sufferers alike, I would be remiss if I failed to mention another company also in a pivotal Ph III trial, whose therapy may in the not too distant future be granted approval for ND-GBM in the US and EU (they are currently not seeking approval for recurrent GBM). That company is Northwest Biotherapeutics (NASDAQ:NWBO).
People that have read any of my previous articles know of my stance on this company: it's very bullish. No reason to dance around that reality. However, the two may be able to coexist peacefully in the GBM space after all (at least in terms of their potential future balance sheets).
Rindo's target population for ND-GBM is around 25%, and a little less for recurrent cases. However, EGFRvIII is also expressed in 78% of breast carcinomas, 73% of ovarian carcinomas, 42% of head and neck squamous cell carcinomas, and 39% of non-small-cell lung cancers. The market for Rindo extends past GBM, and upon approval management will no doubt conduct trials to obtain label extension of their biologic into the above indications as well, expressing a truly massive market share.
All told, this is why they are currently undervalued at around a $1.3B market cap; the now almost certain AA of Rindo for rGBM, which also portends achieving approval for ND-GBM; the value in Rindo to treat the above various indications, and the value in Glemba for TNBC and the up-and-comer Varli.
However, if we look at the potential in NWBO relative to their market cap ($340mm), and consider that Evaluate Pharma ranks their potential WW NPV at $5.7B, with estimated annual sales of DCVax-L for ND-GBM at $2.1B (these figures would nearly double with the addition of recurrent GBM sales), and also consider the recently shown preliminary efficacy found with DCVax-Direct, a very great upside potential also lies with NWBO, despite their less attractive cash position. I've gone over other specifics on them here and here.
Though regarding competition with CLDX, a recent abstract and presentation at the SNO showed that DCVax-L is less effective in the EGFRvIII+ patients that Rindo targets. Therefore it is likely that DCVax-L, should it find approval, will not infringe upon the marketability of Rindopepimut. They may end up splitting this market with 75% going to NWBO and 25% to CLDX. And considering the urgent need in this indication with essentially no effective therapies to prolong patients' survival, deep market penetration is probable.